vimarsana.com
Home
Live Updates
89bio Announces Additional Data from the ENLIVEN Phase 2b Tr
89bio Announces Additional Data from the ENLIVEN Phase 2b Tr
89bio Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis (NASH) at AASLD The Liver Meeting® 2023
—Reductions in key non-invasive tests of liver inflammation and fibrosis support previously demonstrated fibrosis improvements across compensated cirrhotic patients at week 24— —A...
Related Keywords
San Francisco ,
California ,
United States ,
Massachusetts ,
Boston ,
Annie Chang ,
Hank Mansbach ,
Sheryl Seapy ,
Nasdaq ,
Drug Administration ,
Linkedin ,
Lifesci Advisors ,
Exchange Commission ,
Liver Meeting ,
Chief Medical Officer ,
Non Invasive Tests ,
Breakthrough Therapy ,
New England Journal ,
Breakthrough Therapy Designation ,
Annual Report ,
Safe Harbor ,
Private Securities Litigation Reform Act ,
Sci Advisors ,
Markets ,